These findings establish that anti-CD47 Ab promotes the upregulation of CTLA4 levels in NSCLC cells through the regulation of Foxp1, providing a theoretical foundation for combined therapy targeting CD47 and CTLA4 in NSCLC. Here, CD47 is linked to non-small cell lung carcinoma.